SCHEMBL15904148

SCHEMBL15904148

[C]#Cc1ccc(C(=O)N2CCCC(C(=O)O)C2)s1

nearest known ligand 0.47

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 1/20 0.47
GRM3 Q14832 1/20 0.46
ALDH1A1 P00352 5/20 0.44
LMNA P02545 1/20 0.44
GAA P10253 1/20 0.44
L3MBTL1 Q9Y468 2/20 0.43
L3MBTL3 Q96JM7 1/20 0.43
YEATS4 O95619 1/20 0.43
HPGD P15428 4/20 0.43
POLB P06746 1/20 0.43
MAPT P10636 2/20 0.40
HSP90AA1 P07900 1/20 0.40
PKM P14618 1/20 0.40
RXFP1 Q9HBX9 1/20 0.40
MEN1 O00255 1/20 0.40
KMT2A Q03164 1/20 0.40
GLA P06280 1/20 0.39
HSD17B10 Q99714 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15904121 0.75 GRM3 (0.67) MAPK1GRM3ALDH1A1LMNAGAA
SCHEMBL15904192 0.74 L3MBTL1 (0.62) ALDH1A1L3MBTL1L3MBTL3HPGDPOLB
SCHEMBL7233472 0.74 RAB9A (0.64) MAPK1ALDH1A1LMNAGAAMAPT
SCHEMBL15904153 0.73 MAPK1 (0.48) MAPK1GRM3ALDH1A1GAAL3MBTL1
SCHEMBL16442058 0.71 ALDH1A1 (0.64) GRM3ALDH1A1L3MBTL1L3MBTL3HPGD
SCHEMBL7232912 0.71 ALDH1A1 (0.64) GRM3ALDH1A1L3MBTL1L3MBTL3HPGD
SCHEMBL3252541 0.71 HPGD (0.57) ALDH1A1GAAL3MBTL1L3MBTL3YEATS4
SCHEMBL1520334 0.71 ALDH1A1 (0.64) GRM3ALDH1A1L3MBTL1L3MBTL3HPGD
SCHEMBL15904645 0.70 GRM3 (0.51) MAPK1GRM3ALDH1A1L3MBTL1HPGD
SCHEMBL15904228 0.70 GRM3 (0.51) MAPK1GRM3ALDH1A1POLBHSP90AA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9663488-B2 Metalloenzyme inhibitor compounds VIAMET PHARMACEUTICALS, INC. (US) 2017-05-30 US disclosed
US-20150353546-A1 METALLOENZYME INHIBITOR COMPOUNDS Viamet Pharmaceuticals (NC), Inc. 2015-12-10 US disclosed
EP-2948450-A1 METALLOENZYME INHIBITOR COMPOUNDS Viamet Pharmaceuticals, Inc. (US) 2015-12-02 EP disclosed
WO-2014117090-A1 METALLOENZYME INHIBITOR COMPOUNDS VIAMET PHARMACEUTICALS, INC. (US) 2014-07-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150353546-A1 METALLOENZYME INHIBITOR COMPOUNDS MMEL1, GPX1, MPO MAPK1 3450/4885GRM3 1554/4885ALDH1A1 289/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.